Antiseptic Log Reduction Criteria Should Stand, NDAC Recommends
This article was originally published in The Tan Sheet
Executive Summary
Current log reduction criteria to measure the efficacy of topical antiseptic products should not be reduced due to a lack of "compelling" data to support revising the standards, FDA's Nonprescription Drugs Advisory Committee concluded during a March 23 meeting in Gaithersburg, Md
You may also be interested in...
NDAC’s Wood Departs FDA Committee; Joins Private Investment Firm
Nonprescription Drugs Advisory Committee Chairman Alastair Wood, MD, will depart NDAC in May and take a position at New York-based private equity firm Symphony Capital, the company announced May 1
NDAC’s Wood Departs FDA Committee; Joins Private Investment Firm
Nonprescription Drugs Advisory Committee Chairman Alastair Wood, MD, will depart NDAC in May and take a position at New York-based private equity firm Symphony Capital, the company announced May 1
NDAC’s Wood Departs FDA Committee; Joins Private Investment Firm
Nonprescription Drugs Advisory Committee Chairman Alastair Wood, MD, will depart NDAC in May and take a position at New York-based private equity firm Symphony Capital, the company announced May 1